The interval between courses of chemotherapy have classically been kept to a minimum in order to maximize dose intensity. Certain clinical observations suggest that longer intervals, particularly in the high-dose setting, may be more effective. This is based in part on the evidence that resistance is reversible over time and that the interval should be sufficient to allow for such a reversal. Clinical evidence for such reversibility include the following. In metastatic breast cancer, double or double high-dose stem cell rescue (HD-SCR) studies involving a minimal interval, have not, at least as yet, been shown to be superior to single HD-SCR. In Hodgkin's disease, response after relapse correlates directly with duration of time to relapse. In a comparative study of metastatic breast cancer, early HD-SCR preceded by daunorubicin induction was inferior to delayed HD-SCR. The latter was not preceded by induction chemotherapy. In a comparative study of childhood ALL, patients randomized to delayed (4 month interval) intensification had a significantly superior survival as compared to patients randomized to immediate (1 month interval) intensification. Taken together, these clinical observations indicate that resistance is reversible and that optimization of the interval must take this into account. Cytokinetic modeling of those clinical studies also found that delayed HD-SCR could result in a superior effect. Cytokinetic models of minimal residual tumor which were also examined included the Skipper exponential model, the NortonSimon model which emphasizes the Gompertzian effect, the clonal evolution model, and the Retsky-Demisheli model which derives from a bimodal relapse pattern above. Biological and clinical data have resulted in a clinical protocol in the CALGB wherein patients with metastatic breast cancer are randomly allocated to (1) a single HD-SCR arm; (2) a double HD-SCR with a 5-week interval; and (3) a double HD-SCR arm with a 16 week interval.
For cytokinetically aggressive tumors, including Burkitt's lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, small cell lung cancer and testicular cancer, the interval between treatments is critical to the therapeutic effect.
1 Such tumors will often respond rapidly to a course of myelosuppressive chemotherapy only to demonstrate regrowth prior to the next course 3 to 4 weeks later. In this setting, a sustained therapeutic effect requires one or more of the following: higher doses; reducing the interval between treatments and/or interposing non-myelosuppressive therapy between courses of treatment. All of these have the effect of increasing dose intensity. 2 Recent evidence suggests that the interval between treatments for the more common, slow growing, solid epithelial tumors may not follow the above paradigm and may require a different treatment strategy. Experimental and clinical models suggest that following treatment, particularly intensive treatment, the surviving cells are resistant, that such resistance is reversible and that the interval between treatments should allow sufficient time for the reacquisition of tumor sensitivity (see Discussion). Recent studies of time to relapse patterns in primary breast cancer also indicate that the interval between courses of chemotherapy should be reviewed. 3, 4 Important additional questions include: What should be the components of the regimens? Should the two courses be composed of the same agents or should they be different? Does the sequence make a difference? And what should be the interval between the two HD courses? In a companion paper, we examine the importance of sequence. 5 In this paper, we examine the evidence that the interval between courses of chemotherapy affects response to chemotherapy, particularly HD-SCR (high-dose stem cell rescue) therapy.
The interval -relevant clinical observations
The following clinical observations support, and/or are consistent with the concept of delayed recovery of chemosensitivity.
High dose-stem cell rescue (HD-SCR) program in patients with metastatic breast cancer
Second generation HD-SCR studies involved a doxorubicinbased induction followed by high-dose CBP (cyclophos- Figure 1 Response to combination chemotherapy after relapse from first complete remission. CR = complete remission; dCR = duration of complete remission.
phamide, BCNU, cisplatin) or CTC (cyclophosphamide, thiotepa, carboplatin). [6] [7] [8] [9] [10] In patients with metastatic breast cancer who had not received prior non-adjuvant chemotherapy, these and related studies produce a 40 to 60% complete or nearly complete response rate, a doubling of the duration of response, and probably a progression-free survival (PFS) plateau between 10 and 20%. [6] [7] [8] [9] [10] Our cytokinetic extrapolations (see below) and the identification of additional active chemotherapeutic agents appropriate to the high-dose setting prompted us to initiate the double or tandem HD-SCR study which is presented schematically as follows:
The ongoing and published double HD-SCR programs, particularly when given after standard multicycle induction therapy, are insufficiently mature for evaluation of longterm effects. [12] [13] [14] Only two, the neuroblastoma study, 14 and the Bezwoda 9 breast cancer study, are positive in terms of survival. This limited evidence that the second HD-SCR course improves response is consistent with the view that resistance following the first course compromises a significant effect of the second course.
The therapeutic results of the above high-dose studies in patients with breast cancer have been challenged.
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Duration of initial response correlates directly with response to chemotherapy after relapse
What is the clinical evidence that drug resistance is reversible over time? In stages 3B and 4 Hodgkin's disease, combination chemotherapy produces complete remission in 70% of patients, and cure in 40%. 17 For patients who achieve complete remission, the time from end of treatment to relapse is related directly to their responsiveness to chemotherapy in relapse (Figure 1) . 18 In patients who relapsed within 3 months, the complete response rate was only 10%, the duration of response was very short, and cure was not achieved. With increasing time interval between the end of treatment and relapse, there was increasing response. For patients who relapsed late, responsiveness approximated that in de novo treated patients. This finding for Hodgkin's disease may be generalized to essentially all solid tumors wherein complete remission can be achieved either by chemotherapy of metastatic disease or, by local treatment of the primary tumor followed by adjuvant chemo-or hormonal therapy.
The cytokinetic and resistance interpretation of these results will be presented below.
Metastatic breast cancer, early vs delayed high-dose stem cell rescue
In a study by Peters, 19 patients with metastatic breast cancer who achieved complete remission with induction chemotherapy were randomly allocated to receive early HD-SCR or delayed HD-SCR, that is HD-SCR that is HD-SCR at the time of relapse (Figure 2 ). The duration of disease-free survival and overall survival was longer in patients who received delayed HD-SCR. 19 This finding was unexpected considering that delayed HD-SCR was performed in relapse whereas the early intensification was performed when the patients were in complete remission. The patients who received delayed HD-SCR at relapse, did not receive induction chemotherapy (Figure 2 ). While there are several interpretations of these events, 18 a likely one, in our view, is that the long treatment-free interval before the delayed HD-SCR provided time for recovery of tumor cell sensitivity as compared to early HD-SCR which was delivered immediately after induction chemotherapy. 19, 20 AFM ×4 CR no CR off study
Figure 2
Early vs delayed HD-SCR (design by Peters 19 ).
Comparative interval study in acute lymphocytic leukemia
There is one comparative study wherein the interval was a randomized independent variable. 21 Because of provocative phase II results, developed by the Berlin, Frankfurt, Muenster, (BFM Group). 22 CCG (Children's Cancer Group) designed a complex study of pediatric ALL, the relevant part of which follows. 22 After remission induction and consolidation, the patients were randomized to receive intensification chemotherapy either immediately or after an interval of 12 weeks. This study involved only the 50% of patients with intermediate risk stages of ALL. At 5 years, the survival rate for the delayed intensification patients was 73% as compared with 61% in the control group. A greater difference was seen in certain subsets. The study had considerable statistical power and the above differences were significant (P = 0.006). The delayed intensification was not high-dose in the above context, but rather emphasized polychemotherapy including vincristine, doxorubicin, asparaginase, dexamethasone, IT methotrexate, cyclophosphamide and ara-C and thioguanine.
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Dormant tumor cells as a cause of late relapse in patients with primary breast cancer
Recent studies indicate that the hazard function for relapse is bimodal with an early peak at 1-2 years and a late peak at 4-6 years. 3, 4 The late peak is thought to result from dormant cells resistant to chemotherapy. For unknown reasons, such cells undergo delayed activation at 4-6 years. Whether these observations apply to patients treated with metastatic tumor in relapse is not known. The dormant cell problem has been a basis for delayed adjuvant chemotherapy protocols.
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Interpretation of the interval effect and proposed studies
In an effort to provide a basic framework and model for the interval, we considered three items: (1) hypothetical cytokinetic analysis of the interval; (2) modeling and experimental data concerning drug resistance with relation to the interval; and (3) the construction of a clinical trial addressed to the interval.
Hypothetical cytokinetic analysis of the interval
Patients in complete remission, with minimal residual tumor (MRT), are an increasing clinical experience. This is due to improved methods of inducing complete remission as is now possible in the common solid tumors, such as head and neck cancer, breast cancer, small cell lung cancer, esophageal cancer, and ovarian cancer. MRT can now be measured in the marrow and blood with a sensitivity of one tumor cell in 10 6 normal cells. 23 Technical advances that contribute to this sensitivity include integrated computerization, automatic scanning, confocal microscopy and immunofluorescence. 23 A basis for specificity is that keratinpositive cells are not normally present in the marrow and peripheral blood. Related advances include PCR or RT-PCR which are the most sensitive techniques, and the identification of new MRT targets. In treating patients in CR (ie in MRT), in the past, the clinical oncologist has had to 'fly blind'. MRT may, by enumerating tumor burden, light the way toward improved treatment. Since the transition to cure must go through MRT, the effective treatment of MRT is a high priority objective of systemic treatment. The importance and power of measuring MRT was demonstrated initially in choriocarcinoma where cure was made possible by HCG guidance. 24 In Figure 3 , we have illustrated hypothetically the effects of HD-SCR on tumor burden and drug sensitivity. The tumor burden is plotted in Figure 3A . HD-SCR rendered a 7 log kill, which is followed by stability, and finally, by an accelerating ascendancy of the tumor burden. In Figure 3B , hypothetical considerations with respect to drug sensitivity are presented. Following the intensive treatment (the arrow), where a 7 log kill is rendered, the four examples of the evolution of drug resistance/sensitivity, are plotted.
(1) The tumor cells remain sensitive in spite of multilog cell kill (Figure 3a) . This might occur if survival is a random process or more commonly if the tumor cells are transiently protected from drug by, for example, temporary vascular occlusion which is known to occur in solid tumors. 25, 26 This example would predict that early relapse should be as sensitive to chemotherapy as late relapse. This is not the case (as above). (2) The second example (Figure 3b) is that, following a 7 log kill with HD-SCR, reversion to sensitivity occurs very rapidly, that is, within a month. We think this unlikely because it would predict that early relapse should respond as well as late relapse, which again, is not the case. (3) In Figure 3c , drug resistance persisting after a 7 log kill is stable, ie long-term or permanent. We reject this option because it would predict that late relapsers should respond poorly and not better than early relapsers. (4) The truth, we believe, is somewhere between (b) and (c), that is, (d) in Figure 3B . Tumor cells surviving a multilog kill necessary to produce complete remission are likely to be resistant initially, and the longer patients remain in complete remission, the greater the likelihood of reversing drug resistance.
Thus, there is a 'window of opportunity' (d) in Figure 3B , for secondary intensive treatment. That window should have the following properties. It should be the time period during complete remission or MRT when tumor cells have reverted from resistance to sensitivity. If the time for this takes 3 to 4 months, for example, tandem or double SCR therapy, where the interval is 1 month, would not be expected to be effective. The end of the window should be before the underlying tumor burden increases in a major way, certainly, before clinically evident relapse occurs. The 'window of opportunity' should, ideally, include time when the MRT is cytokinetically active, as compared to dormant, since the former cells are more sensitive to chemotherapy.
Cytokinetic models of minimal residual tumor
A number of models of MRT have been proposed. The following reviews these models in relation to our clinical observations. These are considered in Figures 4A-E .
The first quantitative cytokinetic models were developed by Skipper et al in mice bearing L 1210 leukemia, 27 ,28 and applied to clinical leukemia, particularly, and subsequently to Hodgkin's disease and non-Hodgkin's lymphoma. 29 Figure 4(a) represents the pioneering model which indicates the first order kinetic effect of chemotherapy. The implications include (1) expressing tumor burden exponentially; (2) an inverse relationship between curability and tumor burden; and (3) the use of duration of unmaintained complete remission (or time to death for mouse tumors) to estimate tumor cell kill. Both Bezwoda 9 and Peters 19 found in randomized comparative studies, that HD-SCR more than doubled the time to relapse as compared to standard dose control. The Skipper model is a homogeneous tumor, that is L1210 growing in homogenous mice, ie inbred strains. Therefore, it does not reflect the hetereogeneity and slower growth rates of human tumors. Nevertheless, it remains the foundation model on which most of the subsequent ones have been built. 30, 31 In the Norton-Simon model, that is (B) in Figure 4 , tumor regression and most particularly, tumor recovery is Gompertzian. 31, 32 Thus, as MRT increases, the growth fraction and the growth rate progressively decrease. The growth fraction is largely an expression of a proportion of tumor cells in mitotic cycle. Since cycling cells generally are more sensitive to chemotherapy, treatment early during recovery, such as represented by (Figure 4Ba) , would be expected to be more effective in terms of log kill, as compared to treatment late (Figure 4Bb ). This model, therefore, does not fit with the clinical observation that chemosensitivity may increase with time in complete remission. Figure 4C represents a model which is based primarily on clonal evolution. Genetic instability characterizes cancer and is the major therapeutic challenge. This genetic instability (increased recombination rates, mutation rates) results in phenotypic variation among daughter cells. Selection from these variants is based on environmental pressures. Cells that have an increased proliferation rate, would have a survival advantage. Hence, there is an increasing rate of growth with time. This model would be consistent with the fact that upon relapse tumors tend to be more aggressive than initially. Thus, on the basis of cytokinetics, a poor response would be expected early, whereas a substantially greater response would occur later in complete remission. 32, 33 In Figure 4D , the 7 log cytoreduction results in delayed recovery of remaining tumor cells ('stunned'). However, some proportion remain clonogenic with recovery followed by Gompertz and/or clonal evolution recovery and eventual relapse.
In the example presented in Figure 4D , there is a long period of stable MRT followed by exponential growth. Human tumors, such as breast cancer, may relapse beyond 5, and even at 15 to 20 years, following control of the primary tumor. This has been attributed to dormant, G0, mitotically inactive tumor cells. Alternatively, in the absence of angiogenesis, metastatic tumors may grow to 1 mm in diameter, the maximum size permitted by diffusion of oxygen and metabolites. 33, 34 They are cytokinetically active, particularly in the periphery with cell death occurring increasingly towards the necrotic center. 26 Some tumor cells form spheroids in culture which remain stable for long periods of time. Presumably, at some point a mutation occurs which results in the in vivo production of tumor angiogenesis factors. The tumors vascularize and accelerating growth occurs. 33 Such 'pseudodormancy' clinically resembles true dormancy, but because of the cytokinetic turnover, might respond more favorably to chemotherapy. On the other hand, spheroids may be resistant to chemotherapeutic agents as compared to single cell suspensions, a phenomenon known as multicellular resistance. 33 The Retsky-Demicheli model deals further with the dormant cell issue. It derives from the observation that the relapse pattern after primary treatment for breast cancer does not follow Gompertzian or exponential kinetics. Rather, hazard function analysis indicates a bimodal risk with an early peak at 1-2 years and a later peak at 4-6 years. It is proposed that the later peak resulted from tumor cells that survive early chemotherapy because of 'dormancy'. What aspect(s) of pathobiology of micrometastasis, eg antigenesis, account for this interesting observation remains to be determined. 3, 4 Preclinical studies of reversibility of drug resistance Preclinical studies concerning the reversibility of drug resistance are complicated by the multiple biological systems involved, by the different drugs employed, and by the fact that the study of reversibility of resistance was rarely the primary aim of the investigator.
We found similar relationships in our production of resistance to alkylating agents in the five human tumor cell lines. By in vitro selection pressure, a three-to 20-fold increase in resistance occurred. At this point, further selection pressure killed the culture whereas withdrawal of the alkylating agent resulted in rapid reversion to sensitivity. With continuing alkylating agent exposure over 10 to 12 months, stable resistance was achieved.
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Clinical models of the interval
The clinical models, including those which we have cited above, support the concept that reversibility of resistance during complete remission is a major factor in response to subsequent chemotherapy. The clinical experience with Hodgkin's disease and other tumors, as above, demonstrates that the initial duration of response correlates directly with subsequent responsiveness after relapse. One explanation is that those factors which make for greater responsiveness initially are intrinsic to the tumor and affect subsequent responsiveness. This in no way excludes reversibility of resistance as an explanation for the phenomenon. The observation that delayed intensification as compared to early intensification produces a higher response rate and duration of response is consistent with the above. In this case, however, the early HD-SCR was preceded by several months of doxorubicin-based combination chemotherapy, whereas delayed HD-SCR intensification was given without prior induction chemotherapy (Figure 2) .
In the first description of antitumor agent resistance in 1965, Law 37 found that methotrexate selected tumor cells which had the property that permitted survival. This was genetic since it was passed on to daughter cells. In the other broad category of resistance, sometimes referred to as induction, the agent causes 'upstream' cellular damage, eg to DNA. This leads to transcriptional activation and the expression of products which activate 'downstream' events. One facet of the complex of 'downstream' events includes p53 wherein increased expression leads to apoptosis. In chemoinsensitive tumors, p53 is commonly mutated and non-functional, and apoptosis, therefore, does not occur. Thus, both upstream and downstream mechanisms may contribute to the setpoint for chemotherapy sensitivity/ resistance. [38] [39] [40] [41] Various forms of multidrug resistance, including MDR and increase in production of GSH or GST isozymes, which facilitate inactivation of alkylating agents, may occur. Induction of resistance may also result from overexpression of chaperonins, such as heat shock proteins. Indeed, unrelated agents such as ara-C may stimulate resistance to alkylating agents. [38] [39] [40] [41] [42] [43] [44] Increasing evidence that much resistance is multidrug and/or multifactorial would indicate that both selection and induction are commonly involved. This is consistent with the emerging position that induction of resistance is associated with a broad base of cross resistance and is reversible. [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Drug schedule may also influence resistance development. For example, in vitro continuous exposure to MTX results in the rapid development of resistance, whereas intermittent exposure may delay such development. The mechanism of resistance after continuous MTX is usually amplification of the target DHFR gene whereas resistance following intermittent exposure is due to transport or other mechanisms. A somewhat similar schedule effect has been described for the fluoropyrimidines as well. How such scheduling would influence the reversibility of resistance is not known. 47, 48 We have tried in Figure 5 to list and interrelate factors which affect reversibility of resistance. Given the heterogeneity of tumors and the multifactorial nature of cancer, it is probable that many, if not all, the mechanisms listed in Figure 5 apply to a given tumor. Based on the above, a clinical trial which addresses the issues of 1 vs 2 HD-SCRs and the interval between two HD-SCRs has been proposed to the CALGB (Figure 6 ).
